Exploration of interethnic variation in the ibuprofen metabolizing enzyme CYP2C9: a

cautionary guide for treatment of COVID-19 symptoms

Ammar Ali Almarzooq[1]

[1]Galore Consultancy, Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain.

Corresponding author:

Ammar Ali Almarzooq,

Flat 12, Building 144, Road 336, Block 314, Manama, Bahrain.

tel: +973-32171842

email: ammar@galoreconsultancy.com

ABSTRACT

Coronavirus disease 2019 (COVID-19), is a rapidly spreading infectious illness that causes a

debilitating respiratory syndrome. Supportive therapy remains the standard for mild-to-

moderate cases, including treatment with non-steroidal anti-inflammatory drugs (NSAIDs)

e.g. ibuprofen, however such medications may increase COVID-19 complications when used

in patients with acute viral respiratory infections. P450 enzyme CYP2C9 are known to be

involved in the metabolism of NSAIDs, however, their pharmacogenetic data are limited.

This study aims to better understand the genetic landscape of CYP2C9 sequence variation

across different ethnic and geographic groups, in correlation with ibuprofen dosing

guidelines. A cohort of 101 Jordanian Arab samples were retrospectively recruited and

genotyped using Affymetrix DMET Plus Premier Package. This study identified 18 single

nucleotide polymorphisms (SNPs) within CYP2C9 in these Jordanian Arabs, within the

context of over 100,000 global subjects in 417 published reports. Genetic structure analysis

across populations revealed that Jordanian Arabs share the closest CYP2C9 sequence

homology to Near East and European populations. However, European populations are 7.2x

more likely to show impaired ibuprofen metabolism than Sub-Saharan populations, and 4.5x

more likely than East Asian ancestry populations.. This is the most comprehensive and up-to-

date analysis for CYP2C9 allele frequencies across multi-ethnic populations world-wide. The

use of modern genomic tools coupled with a proactive assessment of the most likely gene-

drug candidates will lead to a better understanding of the role of pharmacogenetics for

COVID-19 and more effective treatments.

KEYWORDS: COVID-19, ibuprofen, NSAIDs, pharmacogenomics, population genetics

Introduction

A global pandemic of the novel coronavirus disease 2019 (COVID-19) has caused a global

healthcare crisis resulting from high infection and mortality rates[1]. For suspected or

confirmed cases of COVID-19, requiring urgent care for conditions such as fever and/or sore

throat, pharmacological management may require antibiotics and/or analgesics as an

alternative[2]. In addition, non-steroidal anti-inflammatory drugs (NSAIDs) e.g. ibuprofen, may

be prescribed for the management of pain and fever. However, uncertainty related to

infection etiology and efficacy, and emerging concerns related to the use of common NSAIDs

such as ibuprofen, have presented additional challenges in the treatment of COVID-19[3,4].

Patients in France and Europe showing symptoms of COVID-19 were recommended

paracetamol (acetaminophen) rather than ibuprofen, as treatment with ibuprofen could

exacerbate the condition[3]. Ibuprofen may offer symptomatic relief, and could provide

healthcare professionals additional time to deliver customized care and prevent the spread of

infection. Although this strategy is not always reliable since individuals may respond

differently to similar treatments.

Genetic factors are one of the major contributors to individual or ethnic differences in

drug therapeutic efficacy and toxicity[5,6]. Consequently, host genetics and demography

associated with COVID-19 are crucial aspects of infection and prognosis, hence, integral

medication dosing might need to be altered based on a patient's genetic information[7,8]. There

are several gene variants that alter how an individual's body metabolizes and processes

COVID-19 therapies, potentially increasing the risk of undesirable adverse effects. The

cytochrome P450 enzyme CYP2C9, facilitates metabolism of several NSAIDs including

ibuprofen, and CYP2C9 allele frequencies have been shown to vary substantially across

diverse ethnic groups[9,10].

In March 2020, the Clinical Pharmacogenetics Implementation Consortium (CPIC)

published a pharmacogenetic guideline on NSAIDs, with specific therapeutic

recommendations for celecoxib, flurbiprofen, ibuprofen, fornoxicam, feloxicam, firoxicam,

and fenoxicam based on CYP2C9 phenotype[11]. The phenotype was derived from an activity

score, obtained by the sum of two individual allele scores. Recent meta-analysis of CYP2C9

alleles and ibuprofen concentrations using the Pharmacogenomics Knowledge Base

(PharmGKB), showed strong correlations between the CYP2C9*2 allele (g.47639A>C;

p.(Ile359Leu)) and CYP2C9*3 allele (g.47639A>C; p.(Ile359Leu)) with plasma levels of

ibuprofen[12-16]. Based on these results, PharmGKB assigned the highest level of evidence

(level 1A) to these associations[9], indicating strong evidence of pharmacokinetic (PK) or

pharmacodynamic (PD) alteration[7]. Furthermore, CPIC level A and B gene/drug pairs have

sufficient evidence for at least one prescribing action to be recommended. In contrast, CPIC

level C and D gene/drug pairs are considered as having inadequate evidence for actionability

to have prescribing recommendations. For example, CYP2C8*3 with level C, has insufficient

evidence for recommendations in ibuprofen prescription. However, this study shows that

current pharmacogenomics databases can be leveraged to enhance the identification of

CYP2C9 alleles, and to determine population differences in drug response/toxicity events.

Results from this study have wide ranging impacts on the targeted treatment of COVID-19

patients across broad geographic ranges and ethnic backgrounds, and facilitates drug

development processes.

METHODS

Sample collection

This study retrospectively included 101 unrelated Jordanian participants, of which 54 were

male and 47 were female. After a signed informed consent, a 3ml venous blood sample was

collected in 3ml EDTA tubes from each participant at the Princess Haya Biotechnology

Centre between May 2010 and December 2011. Blood samples were stored at 4°C until DNA

extraction. The Institutional Review Board (IRB) of the Jordan University of Science and

Technology approved this study on 4/7/2013 under registration number 67/2/2013.

DNA extraction and genotyping

Genomic DNA was extracted from each blood sample using the QIAamp DNA Micro Kit

(Qiagen, Hilden, Germany) according to the manufacturer's instructions. The quality of the

purified DNA was determined by using a NanoDrop ND-1000 spectrophotometer (Thermo

Fisher Scientific, Waltham, MA USA).

Genotyping was accomplished using the Affymetrix DMET (Drug Metabolizing

Enzymes and Transporters) Plus Premier microarray assay (Santa Clara, CA, USA) to test for

drug metabolism associations. The DMET array contains 1,936 drug metabolism markers

consisting of 1,931 single nucleotide polymorphisms (SNPs) and five copy number variations

(CNVs) in 225 genes, including 47 phase I enzymes, 80 phase II enzymes, 52 transporters

and 46 other genes. These genetic variants were multiplex genotyped using molecular

inversion probe (MIP) technology[17]. The profiles for the genotyping call rates and

concordance comparisons, were generated by the DMET console software v1.3 (Thermo

Fisher Scientific, Inc., Waltham, MA, USA), based on the Bayesian robust linear model with

Mahalanobis (BRLMM) distance classifier algorithm[18,19]. Genotypes were determined for

each SNP site and reported as homozygous wild-type, heterozygous, homozygous variant,

and 'no call' in the case of a lack of genotype call. SNPs with a call rate of less than 99%

were excluded from subsequent analyses. Statistical and genetic analyses were performed for

selection and validation using Microsoft Excel and SPSS v16. Linkage disequilibrium (LD)

analysis was performed to identify non-random SNP associations between populations. LD

was in concordance with all worldwide-distributed 1kG-p3 populations[20]. The genotype and

allele frequencies were calculated and tested using the chi-square (χ^2) test and the Hardy–

Weinberg equilibrium formula ($p > 0.05$). The workflow applied in this study is

summarized in Supplementary material file (Fig. S1).

Selection of CYP2C9 variants

LD analysis was performed using the LDlink tool to generate D' and r^2 values[21], and a matrix

was generated for visualization. These allele frequencies were compared to 139 different

CPIC reports from European and Near Eastern population groups (Table S1). The statistical

comparison of allele frequencies on experimental data and reference populations were

performed by Pearson's χ^2 test with Bonferroni correction and the negative logarithm of the

adjusted significance values [-log10 (adj.p.val)] using the R statistical package v3.6.2 with

ggplot2 and visualized using Rstudio v1.3.1056 (Boston, MA). The assembled DNA flanking

sequence for each of the SNP loci was also subjected to BLAT[22] to determine the specificity

of the array's probes matched to the target sequence set. A probe alignment was considered to

be specific if 40 consecutive base pairs of the probe were fully aligned with the target

sequence[17]. In order to detect the homologous sequences, which likely result in false-positive

or false-negative variant calls, sequence similarity searches were performed using the

Ensembl BLAST/BLAT search programs with default parameters.

Population structure analyses

To identify cryptic relatedness from the genomic data, principal component analysis (PCA)

was performed using the base R function "prcomp" within the R software package and

multidimensional scaling (MDS) plots were generated from the PCA results using ggfortify

and ggplot2[23]. Cryptic population structure was inferred using CYP2C9 SNP data to identify

the ancestral relatedness between the Jordanian Arab population and three defined datasets:

1,810 individuals from 22 populations from the 1000 Genomes Project Phase III (1kG-p3)

dataset, excluding admixed populations (Table S2); 3,413 individuals from 18 global reports

(Table S3); and 31,880 individuals from 118 reports from the European (EUR) and Near

Eastern (NEA) populations from the CPIC updated report in March 2020. For a detailed

description, refer to the supplementary material.

Fixation Index (Fst) was used to quantify population differentiation from genetic

structure using SNP allele frequencies. The R package "BEDASSLE" function was used to

assess genetic similarity between ethnic populations by generating pairwise Fst values (0

indicates no divergence, 1 indicates complete separation) between the Jordanian Arab

population and the other populations listed above[23].

Pharmacogenetic analyses

The frequencies of the 13 actionable pharmacogenomics biomarkers were assessed

cumulatively for the Jordanian Arabs against nine biogeographical groups, consisting of

101,407 individuals from 412 global populations[11,24]. The total frequency of two SNPs with

a Level 1A for the Jordanian Arab population within nine geographically-defined groups

were mapped for global impact visualization of allele frequency on ibuprofen response

(Supplementary material file). Inferred frequency for CYP2C9*1 was excluded from our

biogeographical analyses as no population studies have tested for all known variant alleles,

and *1 was not genotyped directly in many studies[11] (see Supplemental Material for

populations details).

RESULTS

Selection and analysis of CYP2C9 Variations

It is worth mentioning that we have screened all the variants listed in Table S5 for variants

fulfilling our selection criteria to ensure that our pipeline had not missed any known causal or

candidate variants in this gene. Four CYP2C9 variants across 101 Jordanian individuals of

Arab descent associated with reduced enzyme function were selected (Table S5 and S6). The

defective allele *2 was the most abundant variant (0.094), followed by allele *3 (0.084). In

addition, two rare variants, g.55323A>T; and g.55221C>T; were also detected. These two

SNPs had frequencies of less than 0.05. CYP2C9 *2 and *3 together accounted for 0.178 of

the allele frequency and about 0.327 of the reduced or non-functional genotype/phenotype

associations. The four genotype frequencies CYP2C9 *1/*1, *1/*2, *1/*3 and *2/*3 were

0.673, 0.158, 0.139 and 0.03, respectively. Moreover, the genotype frequencies showed no

deviation from HWE ($p > 0.05$; Table 1).

Significant D' values were observed spanning the entire genomic region, following

LD measurements for pairs of SNPs distributed across the 52-kb region. Most allele pairs of

CYP2C9 have a D$^{'}$ value equal to 1.0 (indicating complete LD), whereas, r^2 values across the

same region, show a LD block between the *7 allele (g.5080C>A) at exon 1 and the *14

allele (g.8577G>A) at exon 3. A clear LD block was also observed between CYP2C9*3

(g.47639A>C) at exon 3 and between g.55323A>T at exon 9, crossing an approximately 8-kb

region (Fig. 1A and Table S7). The experimental allele of CYP2C9*7 (g.5080C>A;

p.(Leu19Ile)) was significantly different from the other sampled populations ($p = 4.9 \times 10^{22}$;

Table S8). However, the nucleotide BLAT search showed that the DNA sequence obtained

from the flanking region of this SNP (124 bp) had 100% sequence identity with the

CYP2C19 genes at the region of 10:94762716-94762839. Therefore, this variant was

excluded from the analyses since the individual probes in the MIP assay only bind to a

genomic footprint of ~40 bp. Thus, the homologous sequences would likely result in false-

positive or false-negative variant calls[17].

Genetic structure of CYP2C9 across populations

The two leading principal components from the 14 variants shared between the Jordanian

Arab population and the 22 global populations from the 1000 Genomes Project Phase III

(1kG-p3) dataset (Fig. 2A), captured 60.63% and 21.38% of the variance respectively,

showing a well-defined separation between the Jordanian Arab population and African, East

Asian, and South Asian super populations. The Jordanian Arab population had a close

affinity with European populations, and validated by pairwise Fst analyses (Table S9). The

lowest level of differentiation was observed between the Jordanian Arab population and

British in England and Scotland (Fst = 5.97×10^{-3}), followed by Iberian (Fst = 6.39×10^{-3}) and

Finnish in Finland (Fst = 6.69×10^{-3}) populations, whereas the greatest divergence was

observed with Gambian in western divisions in the Gambia (Fst = 8.54×10^{-2}).

Lack of genomic data for additional ethnic groups in the 1000 Genomes Project such

as near eastern populations, can reduce robustness and potentially result in biased

geographic-based genomic analysis. Therefore, a secondary analysis was performed to

include under-represented populations. The two leading principal components shared

between the Jordanian Arab population, and the 18 global reports including the Near Eastern

population for *1, *2 and *3 captured 98.35% and 1.62% of the variance, respectively,

suggesting a well-defined genetic separation between Jordanian Arabs and African and East

Asian populations (Fig. 2B). In addition, defined clusters of European and Near Eastern

populations were found, which were further validated using pairwise Fst analyses (Table

S10). The lowest level of differentiation was observed between the Jordanian Arab

population and Saudi Arabian population (Fst = 7.4×10^{-4}), followed by Italian (Fst = $1.62 \times 10^{-}$

^{3}) and Turkish populations (Fst = 1.8×10^{-3}), whereas the greatest divergence was observed

with the Korean population (Fst = 1.13×10^{-1}).

These findings were investigated further by increasing the coverage of the variant

analysis to include populations from 118 reports across European and Near Eastern groups.

MDS analysis showed that Jordanian Arabs cluster with Turkish, Israeli, Caucasian, Italian,

Romanian, Iranian and Lebanese populations (Fig. 2C).

Pharmacogenetic analyses by biogeographic grouping system

Across the nine biogeographical groups, 27% of subjects were of East Asian origin, followed

by Europeans (26%), South Central Asians (13%), Near Easterns (12%), Americans (7%),

Latinos (6%), African Americans/Afro-Caribbeans (4%), Sub-Saharan Africans (4%), and

Oceanians (1%; Table S11). Distinct differences were found among these populations, with

direct impacts on ibuprofen clinical outcomes (Fig. 3B). The CYP2C9 *2 and *3 allele

frequencies were significantly higher in the Central/South Asian origin (0.224), followed by

Near Easterns (0.212), Europeans (0.203), Jordanian Arabs (0.178), and Latinos (0.116),

indicating a decreased metabolism and clearance of ibuprofen as compared to Americans

(0.064), Oceanians (0.045), East Asians (0.04), African Americans/Afro-Caribbeans (0.036)

and Sub-Saharan Africans (0.024; Table S12). These significant variant alleles and genotypes

were classified as PharmGKB Level 1A evidence with reduced enzyme function, therefore

are associated with recommended changes to ibuprofen dosing[7]. Interpretation of the

translation into specific dosing guidelines for individual ibuprofen-diplotype pairs[7,11] showed

that European populations are 7.2x more likely to show impaired CYP2C9 metabolism than

Sub-Saharan populations, and 4.5x more likely than East Asian populations (Tables S13 and

S14).

Interestingly, a large number of generally less common alleles were also identified

(Table S15). Allele *9 (g.15560A>G) was significantly over-represented in Sub-Saharan

Africans (0.13), but was not detected in other global populations (Fig. 3A). Alleles *5

(g.47644C>G), *6 (g.15626delA), *8 (g.3260T>C; g.8652G>A; g.8652G>T) and *11

(g.47567C>T) were significantly over-represented in African populations (Sub-Saharan

African and African Americans/Afro-Caribbean) and under-represented in other populations.

East Asian populations over-represented alleles *42 (g.8573C>T) and *55 (g.47645C>A)

(Tables S16 and S17).

DISCUSSION

Although no direct evidence of pharmacogenomics data in patients with COVID-19 was

available at the time of writing this manuscript, there are plausible mechanisms by which

genetic determinants may play a role in adverse drug responses. Having diverse population

genetic information and genetic databases, could help clinicians avoid additional risks for

treating COVID-19 patients. In this work, several genetic markers were analyzed across

diverse ethnic backgrounds to identify population differences in drug responses and toxicity

events associated with ibuprofen treatment. Moreover, controversy arose on the use of

ibuprofen due to the possibility of a worse COVID-19 prognosis[3,4]. Results from this study

showed that pharmacogenomics studies can be leveraged to enhance the understanding of

adverse reactions to the treatment of COVID-19 symptoms and support advancement of drug

development pipelines.

Approximately 33% within 101 individuals of Jordanian Arab descent were either

intermediate or poor metabolizers of ibuprofen based on the sequence variant analysis of

CYP2C9. The g.55323A>T marker was also found to be in LD with the variant of

CYP2C9*3 (Fig. 1A, Table S7), which is consistent with the recently published PharmVar

change adding g.55323A>T to the *3 haplotype definition[25]. The CYP2C9*7 was

significantly different from other populations, and the nucleotide BLAT search revealed a

100% sequence identity with CYP2C19. Further analysis indicated that the array probe used

for genotyping was not able to bind specifically with the target SNP, due to non-specific

binding to another genomic region. Awareness of problematic regions is critical during test

design and reporting to guide decision regarding exclusion of regions and/or whether

alternative assays must be used. This is particularly the case for CYP2C9*7, where both

statistical and genetic tests revealed a homologous sequence that may result in false positive

or false negative variant calls.

MDS analysis showed that the Jordanian Arab population clustered with multiple

regions within European and Near Eastern. MDS results were further validated by the

pairwise Fst values, where the lowest level of differentiation was observed between the

Jordanian Arab population and Saudi Arabian followed by the Italian and Turkish.

Collectively these results showed that the current Jordanian population today falls into two

main groups: one sharing more genetic characteristics with modern-day Europeans and

Central Asians, and the other with closer genetic affinities to Arabia[26]. These autosomal

analyses are in agreement with recent studies using large-scale genomics that indicated three

major genetic events related to Levant populations, including Jordanian. During the late

neolithic, gene pools across Anatolia and the Southern Caucasus mixed, resulting in an

admixture cline[27]. The second event occurred during the Early Bronze Age, where Northern

Levant populations, a region flanked by the Middle East and Europe, experienced gene flow

in a process that likely involved a yet to-be-sampled neighboring population from

Mesopotamia[27]. The most recent event for the modern Levant was largely determined by

subsequent repopulations and mass movements associated with multiple cultural changes

within the last two millennia. This appeared to have facilitated and maintained admixture

between culturally different populations[28]. Conversion of the region's populations to Islam,

appeared to have also introduced major rearrangements in the populations genetic relations

with an admixture of culturally similar populations[26]. In general, the Jordanian population

was not significantly different from their Levantine neighbours, and fit consistently into a

Middle East-Anatolia-Balkan-Caucasus geographic and genetic continuum[29].

Mapped frequencies of CYP2C9 genotypes of *2 and *3 alleles based on both the

PharmGKB meta-analysis[7,12-16] and the CPIC updated report[11], showed that European

populations were 7.2x more likely to show impaired CYP2C9 metabolism than Sub-Saharan

populations, and 4.5x more likely than East Asian ancestry populations (Fig. 4, Table S13).

Inference that a higher proportion of East Asian and African ancestry populations have

normal ibuprofen metabolism, and therefore are less susceptible to complications for

ibuprofen-based treatment.

These findings are supported by recent European reports of potential harm with

ibuprofen usage in patients with COVID-19 symptoms[3]. Further supported by multiple

reports, the National Agency for the Safety of Medicines and Health Products (ANSM) of

France, issued a warning in April 2019 about the use of NSAIDs for patients with infectious

diseases based on an analysis of 20 years of safety data of ibuprofen and ketoprofen.

Consequently, the French regulatory body was concerned that existing infections might be

worsened by the use of these two NSAIDs[30]. Following this analysis, the European

Committee in charge of risk assessment and pharmacovigilance (PRAC) concluded in April

2020 that taking ibuprofen or ketoprofen (oral, rectal or injectable) can lead, in certain

infections, to mask symptoms such as fever or pain, leading to a delay in the management of

the patient with the consequence of a risk of complications of the infection. The PRAC also

concluded that this risk has been observed for bacterial infections in the context of

chickenpox and pneumonia[30]. Furthermore, one large case-control study found a clear

association between NSAIDs and respiratory complications, regardless of whether the

NSAIDs were taken long term or as a treatment for acute illness, suggesting that the

association was not simply a result of increased prescription in response to acute illness[31].

However, additional research is necessary to clarify whether further variants should

be incorporated into clinical decision making. Collectively, this work demonstrates the

capability and application of large-scale pharmacogenomics studies to elucidate genetic

variation effects on NSAID efficacy in COVID-19 patients. Ultimately, the implementation

of pharmacogenetics in clinical settings can leads to more efficient, safer, and cost-effective

treatments.

ACKNOWLEDGEMENTS

Microarray wet- and dry-lab procedures were all performed by the Princess Haya

Biotechnology Centre (PHBC) at Jordan University of Science and Technology (JUST). This

work used data from an approved project by JUST (project 67/2/2013).

CONFLICT OF INTEREST

The author declares that there is no conflict of interest.

FUNDING

No funding was available for this study.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, *et al*. A Novel Coronavirus from
Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382:** 727-733.

2. Lin L, Li TS. Interpretation of "Guidelines for the Diagnosis and Treatment of Novel
Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial
Version 5)". *Zhonghua Yi Xue Za Zhi* 2020; **100:** 805-807.

3. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors
and scientists. *BMJ* 2020; **368:** m1086.

4. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus
at increased risk for COVID-19 infection? *Lancet Respir Med* 2020; **8:** e21.

5. Gray JA. The shift to personalised and population medicine. *Lancet* 2013; **382:** 200-
201.

6. Peterson JF, Roden DM, Orlando LA, Ramirez AH, Mensah GA, Williams MS.
Building evidence and measuring clinical outcomes for genomic medicine. *Lancet*
2019; **394:** 604-610.

7. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, *et al*. The importance
of race and ethnic background in biomedical research and clinical practice. *N Engl J*
Med 2003; **348:** 1170-1175.

8. Gemmati D, Tisato V. Genetic Hypothesis and Pharmacogenetics Side of Renin-
Angiotensin-System in COVID-19. *Genes (Basel)* 2020; **11**: 1044.

9. Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug
disposition and response: review of recently approved drugs. *Clin Pharmacol Ther*
2015; **97:** 263-273.

10.   Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF *et al.*

Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther*

2012; **92:** 414-417.

11.   Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, *et al.* Clinical

Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and

Nonsteroidal Anti-Inflammatory Drugs. *Clin Pharmacol Ther* 2020; **108:** 191-200.

12.   Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual

variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450

2C8 and 2C9 amino acid polymorphisms. *Clin Pharmacol Ther* 2004; **76:** 119-127.

13.   Karazniewicz-Lada M, Luczak M, Glowka F. Pharmacokinetic studies of enantiomers

of ibuprofen and its chiral metabolites in humans with different variants of genes

coding CYP2C8 and CYP2C9 isoenzymes. *Xenobiotica* 2009; **39:** 476-485.

14.   Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J.

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen

pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. *Clin Pharmacol*

Ther 2002; **72:** 62-75.

15.   López-Rodríguez R, Novalbos J, Gallego-Sandín S, Román-Martínez M, Torrado J,

Gisbert JP, *et al.* Influence of CYP2C8 and CYP2C9 polymorphisms on

pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric

forms of ibuprofen in healthy volunteers. *Pharmacol Res* 2008; **58:** 77-84.

16.   Ochoa D, Prieto-Pérez R, Román M, Talegón M, Rivas A, Galicia I, *et al.* Effect of

gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of

ibuprofen enantiomers. *Pharmacogenomics* 2015; **16:** 939-948.

17.   Wang Y, Cottman M, Schiffman JD. Molecular inversion probes: a novel microarray

technology and its application in cancer research. *Cancer Genet* 2012; **205:** 341-355.

18.   Rabbee N, Speed TP. A genotype calling algorithm for affymetrix SNP arrays.

396   *Bioinformatics* 2006; **22:** 7-12.

397   19.   Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology

398   and pharmacogenetics in a genomics era: the DMET platform. *Pharmacogenomics*

399   2010; **11:** 89-103.

400   20.   1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP,

401   Kang HM, *et al*. A global reference for human genetic variation. *Nature* 2015; **526:**

402   68-74.

403   21.   Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-

404   specific haplotype structure and linking correlated alleles of possible functional

405   variants. *Bioinformatics* 2015; **31:** 3555-3557.

406   22.   Kent WJ. BLAT--the BLAST-like alignment tool. *Genome Res* 2002; **12:** 656-664.

407   23.   R Core Team. R: A language and environment for statistical computing. R Foundation

408   for Statistical Computing. 2013. https://www.r-project.org

409   24.   Huddart R, Fohner AE, Whirl-Carrillo M, Wojcik GL, Gignoux CR, Popejoy AB, *et*

410   *al*. Standardized Biogeographic Grouping System for Annotating Populations in

411   Pharmacogenetic Research. *Clin Pharmacol Ther* 2019; **105:** 1256-1262.

412   25.   Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein

413   TE, *et al*. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the

414   Human Cytochrome P450 (CYP) Allele Nomenclature Database. *Clin Pharmacol*

415   *Ther* 2018; **103:** 399-401.

416   26.   Haber M, Gauguier D, Youhanna S, Patterson N, Moorjani P, Botigué LR, *et al*.

417   Genome-wide diversity in the levant reveals recent structuring by culture. *PLoS Genet*

418   2013; **9:** e1003316.

27.   Skourtanioti E, Erdal YS, Frangipane M, Balossi Restelli F, Yener KA, Pinnock F, *et*

al. Genomic History of Neolithic to Bronze Age Anatolia, Northern Levant, and

Southern Caucasus. *Cell* 2020; **181:** 1158-1175.

28.   Scozzari R, Cruciani F, Pangrazio A, Santolamazza P, Vona G, Moral P, *et al*. Human

Y-chromosome variation in the western Mediterranean area: implications for the

peopling of the region. *Hum Immunol* 2001; **62:** 871-884.

29.   Flores C, Maca-Meyer N, Larruga JM, Cabrera VM, Karadsheh N, Gonzalez AM.

Isolates in a corridor of migrations: a high-resolution analysis of Y-chromosome

variation in Jordan. *J Hum Genet* 2005; **50:** 435-441.

30.   ANSM. Nonsteroidal anti-inflammatory drugs (NSAIDs) and serious infectious

complications - Information point updated on 20/05/2020. 2020.

https://www.ansm.sante.fr/S-informer/Points-d-information-Points-d-

information/Anti-inflammatoires-non-steroidiens-AINS-et-complications-

infectieuses-graves-Point-d-Information-actualise-le-20-05-2020.

31.   Basille D, Thomsen RW, Madsen M, Duhaut P, Andrejak C, Jounieaux V, *et al*.

Nonsteroidal Antiinflammatory Drug Use and Clinical Outcomes of Community-

acquired Pneumonia. *Am J Respir Crit Care Med* 2018; **198:** 128-131.

FIGURE LEGENDS

Figure 1: CYP2C9 genetic interpretation in the context of Linkage Disequilibrium (LD) and

high homology sequence. **A.** LD (D' and r^2) between 13 single nucleotide polymorphisms

(SNPs) in the CYP2C9 gene. **B.** Statistical comparison of allele frequencies on experimental

data and reference populations. Color intensity indicates a more significant difference

between the given experimental data and the population.

Figure 2: Population structure analysis of the CYP2C9 *1, *2 and *3 alleles. **A.** MDS plot of

the 14 variants shared between the Jordanian Arab population and 22 global populations from

the 1000 Genomes Project Phase III (1kG-p3) dataset. **B.** MDS plot of the Jordanian Arab

population and 18 public worldwide populations. **C.** MDS plot of the Jordanian Arab

population and 118 populations from the Near Eastern (ESN) and European (EUR) groups.

Figure 3: Biogeographical groups and pharmacogenetic analyses for CYP2C9 and ibuprofen

associations. **A.** Frequencies of 13 actionable pharmacogenomics (PGx) alleles and

phenotypes assessed cumulatively for the Jordanian Arab population against the nine

biogeographical groups. **B.** Mapping of the total allele and phenotype frequency of the

CYP2C9 alleles *2 and *3.

Figure 4: Global frequency map of variability in of CYP2C9 level A alleles and impact on

ibuprofen response. Phenotype prevalence shown for global populations of CYP2C9*2 and

*3. The two admixed groups of African American/Afro-Caribbean and Latino were not

represented on this figure as the geographical grouping based on the location of genetic

ancestors pre-diaspora and pre-colonization could not be applied to the two admixed groups.

A.

B.

Chromosome 10 Coordinate (Mb) (NG_008385.1)

CYP2C9 Gene

-Log (Adj. p-value)

BLAT

CYP2C9*7

TTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTT
CAATCTGGAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCT
GGCCCCACTCCTCTCCCAGTGATTGGAAATATCCTACAGAT

100% sequence identity with 124bp at CYP2C19

*Current Study

A. CYP2C Core Alleles

Legend: *2, *3, *5, *6, *8, *9, *11, *42, *55, Others

Left panel (% Allele), top to bottom: Oceanian, East Asian, American, African American/Afro-Caribbean, Latino, Jordanian*, European, Near Eastern, Central/South Asian, Sub-Saharan African

Right panel (% Phenotype): Abnormal/Priority/High Risk, Normal, Unknown — Oceanian, East Asian, American, African American/Afro-Caribbean, Latino, Sub-Saharan African, Jordanian*, European, Near Eastern, Central/South Asian

X-axis left: 0.30 – 0 (% Allele); X-axis right: 0.5 – 0 (% Phenotype)

B. Ibuprofen Level 1A

Legend: *2, *3

Left panel (% Allele), top to bottom: Sub-Saharan African, African American/Afro-Caribbean, East Asian, Oceanian, American, Latino, Jordanian*, European, Near Eastern, Central/South Asian

Right panel (% Phenotype): Abnormal/Priority/High Risk, Normal, Unknown — Sub-Saharan African, African American/Afro-Caribbean, East Asian, Oceanian, American, Latino, Jordanian*, European, Near Eastern, Central/South Asian

X-axis left: 0.25 – 0 (% Allele); X-axis right: 0.5 – 0 (% Phenotype)

*Current Study

Table 1. Distribution of CYP2C9 alleles and genotypes in Jordanian Arabs (NG_008385.1; NP_000762.2).

Allele	Variant	Substitution	Allele Count	Allelic Frequency	Genotype	Genotypic Frequency	Observed Genotypes	Expected Genotypes	χ^2	p-value
*2	g.8633C>T; p.(Arg144 Cys)	C	183	0.91	CC	0.81	82	82.89	1.09	0.58
		T	19	0.09	CT	0.19	19	17.21		
					TT	0	0	0.89		
*3	g.47639A >C; p.(Ile359 Leu)	A	185	0.92	AA	0.83	84	84.72	0.85	0.65
		C	17	0.08	AC	0.17	17	15.57		
					CC	0	0	0		